ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

In a move advertised as being in line with FDA’s goal of “radical transparency,” the agency July 10 announced the publication of more than 200 complete response letters.

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

John P. Leonard, an expert in lymphoma and other blood cancers, was named director of the Center for Blood Cancers and chief of the Division of Hematology and Medical Oncology in NYU Grossman School of Medicine’s Department of Medicine. The Division of Hematology and Medical Oncology is a major clinical arm of the Perlmutter Cancer Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Study findings expand donor pool for blood cancers

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options.

July 03, 2025

Vol.51 No.26

Drugs & Targets

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA has approved Zegfrovy (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

July 03, 2025

Vol.51 No.26

Drugs & Targets

FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM

FDA has granted accelerated approval to linvoseltamab-gcpt, trade name Lynozyfic, a bispecific B-cell maturation antigen-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

July 03, 2025

Vol.51 No.26

ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

Study findings expand donor pool for blood cancers

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM

Renew today!

Subscriber content

Never miss an issue!

Login

ODAC gives thumbs-up to imetelstat for MDS, upholding the value of transfusion independence

YOU MAY BE INTERESTED IN

Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

John Leonard named director of Center for Blood Cancers, chief of Division of Hematology and Medical Oncology at NYU Langone

Study findings expand donor pool for blood cancers

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA grants accelerated approval to linvoseltamab-gcpt for r/r MM

Never miss an issue!

Login

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology